Company Encyclopedia
View More
name
GRAIL
GRAL.US
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, it develops minimal residual disease post-diagnostic tests.
1.945 T
GRAL.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking73/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-16.83%E
    • Profit Margin-286.43%E
    • Gross Margin54.54%B
  • Growth ScoreB
    • Revenue YoY20.53%B
    • Net Profit YoY80.81%A
    • Total Assets YoY-16.58%E
    • Net Assets YoY-13.44%E
  • Cash ScoreC
    • Cash Flow Margin-34.91%D
    • OCF YoY20.53%B
  • Operating ScoreE
    • Turnover0.05E
  • Debt ScoreA
    • Gearing Ratio13.88%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Creative Planning Takes $725,000 Position in GRAIL, Inc. $GRAL

    Creative Planning purchased a new stake in GRAIL, Inc. (NASDAQ:GRAL) worth $725,000 in the second quarter. Other investors, including Police & Firemen's Retirement System of New Jersey and Geode Capital Management, also increased their positions. GRAIL's stock performance has been strong, with a recent price of $97.38. The company reported better-than-expected earnings and has received mixed ratings from analysts. Insiders have sold shares recently, and the company targets the $100B cancer market.

    Market Beat·
    US
    GRAL
    -3.59%
    Market Beat·
    US
    GRAL
    -3.59%

    Grail Grants RSUs to New Employees Under Inducement Equity Plan

    GRAIL, Inc. has granted RSUs for 21,570 shares to 21 new non-executive employees under its Inducement Equity Plan. The RSUs will vest over four years, with 25% vesting on November 30, 2026, and the rest annually, contingent on continued employment. This information was published by Grail Inc. via PR Newswire on December 01, 2025.

    Reuters·
    US
    GRAL
    -3.59%
    Reuters·
    US
    GRAL
    -3.59%

    The Nasdaq Biotechnology Index fell by more than 2%. Among them, Sutro Biopharma dropped 12.98%, Kyverna Therapeutics fell 10.95%, GRAIL decreased 10.01%, and Pyxis Oncology declined 9.34%. Ironwood Pharma rose 4.44%, Arrowhead Pharmaceuticals increased 4.63%, Neumora Therapeutics grew 6.92%, and Q32 Bio surged 92.69%

    Wallstreetcn·
    US
    IRWD
    -7.10%
    US
    STRO
    -7.29%
    US
    NMRA
    -2.42%
    Wallstreetcn·
    US
    IRWD
    -7.10%
    US
    STRO
    -7.29%
    US
    NMRA
    -2.42%

    The Nasdaq Biotechnology Index closed up more than 1.4%. Among the constituent stocks, Cullinan Oncology LLC rose 36.54%, Relay Therapeutics Inc. rose 20.68%, GRAIL rose 18.81%, and Lyell Immunopharma rose 18.71%. Meanwhile, Anavex Life Sciences fell 5.52%, Neumora Therapeutics fell 7.30%, and Arcellx fell 16.89%

    Wallstreetcn·
    US
    LYEL
    -2.32%
    US
    CGEM
    -0.09%
    US
    RLAY
    -3.88%
    Wallstreetcn·
    US
    LYEL
    -2.32%
    US
    CGEM
    -0.09%
    US
    RLAY
    -3.88%

    GRAIL (NASDAQ:GRAL) Shares Gap Down - Here's What Happened

    GRAIL, Inc. (NASDAQ:GRAL) shares gapped down, opening at $78.62 from a previous close of $84.94, last trading at $76.19. Analysts have mixed ratings: Guggenheim upgraded to 'buy' with a $100 target, UBS set a $75 objective, Weiss Ratings issued a 'sell' rating, and Canaccord Genuity raised its target to $105. Insiders sold shares, and institutional investors adjusted holdings. GRAIL targets early cancer detection with a market cap of $3.11 billion.

    Market Beat·
    US
    GRAL
    -3.59%
    Market Beat·
    US
    GRAL
    -3.59%
    © 2025 Longbridge｜Disclaimer